Kushner, Pamela R.
DeMeis, Jane
Stevens, Petrina
Gjurovic, Ana Marija
Malvolti, Elmas
Tangri, Navdeep
Funding for this research was provided by:
AstraZeneca
Article History
Received: 15 November 2023
Accepted: 16 January 2024
First Online: 5 March 2024
Declarations
:
: Jane DeMeis has no conflicts of interest to disclose. Petrina Stevens, Ana Marija Gjurovic, and Elmas Malvolti are employees and shareholders of AstraZeneca. Pamela R. Kushner has received speakers bureau and advisory board fees from AstraZeneca, Eli Lilly and Company, and Novo Nordisk A/S, speaker fees from Bayer AG, and honoraria from AstraZeneca and Eli Lilly and Company. Navdeep Tangri has received grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., and Tricida, Inc., has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., and Tricida, Inc., and holds stock options from Mesentech, Inc., PulseData, Inc., Renibus Therapeutics Inc., and Tricida, Inc.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.